Related Experiment Videos
Blood-brain barrier phenylalanine transport and individual vulnerability in phenylketonuria
H E Möller1, J Weglage, D Wiedermann
1Center for In Vivo Microscopy, Duke University Medical Center, Durham, North Carolina 27710, USA.
Insights
Phenylketonuria (PKU) patients show varied brain phenylalanine (Phe) levels. Differences in Phe transport and metabolism kinetics explain individual vulnerability to PKU, impacting clinical outcomes.
Area of Science:
- Biochemistry
- Neuroscience
- Medical Physics
Background:
- Phenylketonuria (PKU) is a genetic disorder characterized by the inability to metabolize phenylalanine (Phe).
- Intracerebral Phe accumulation is linked to neurological deficits in PKU patients.
- Understanding PKU's impact on brain Phe levels is crucial for managing the condition.
Purpose of the Study:
- To measure intracerebral phenylalanine (Phe) concentrations in patients with phenylketonuria (PKU) using in vivo nuclear magnetic resonance spectroscopy.
- To correlate stationary and dynamic Phe levels with individual clinical outcomes in PKU patients.
- To investigate the kinetic differences in Phe transport and metabolism between typical PKU patients and those with milder phenotypes.
Main Methods:
- In vivo nuclear magnetic resonance (NMR) spectroscopy was employed to quantify brain Phe concentrations.
- Measurements included stationary Phe levels under free nutrition and time courses after an oral Phe load (100 mg/kg).
- Kinetic parameters, including transport Michaelis constants (Kt,app) and the ratio of brain influx to consumption rates (T(max)/v(met)), were analyzed.
Main Results:
- PKU patients with typical clinical outcomes had brain Phe levels ranging from 0.41 to 0.73 mmol/L at blood Phe concentrations around 1.2 mmol/L.
- Three untreated, normally intelligent adult women with PKU exhibited significantly lower brain Phe levels (<0.15 mmol/L).
- These women showed higher Kt,app values (0.45–1.10 mmol/L vs. 0.10 mmol/L) and lower T(max)/v(met) ratios (2.55–3.19 vs. 7.8–14.0) compared to typical PKU patients.
Conclusions:
- Individual variations in brain Phe transport and metabolism kinetics are significant factors in PKU vulnerability.
- These kinetic differences can explain the wide spectrum of clinical outcomes observed in PKU patients.
- In vivo NMR spectroscopy is a valuable tool for assessing brain Phe dynamics and understanding PKU pathophysiology.
Abstract:
In vivo nuclear magnetic resonance spectroscopy can be used to measure intracerebral phenylalanine (Phe) concentrations in patients with phenylketonuria (PKU). Stationary levels, obtained under free nutrition, as well as time courses after an oral Phe load (100 mg/kg) were investigated in 11 PKU patients and were correlated with the individual clinical outcome. At blood levels around 1.2 mmol/L, brain Phe was 0.41 to 0.73 mmol/L in clinically "typical" patients, but less than 0.15 mmol/L in three untreated, normally intelligent, adult women. Kinetic investigations revealed higher transport Michaelis constants and lower ratios of the brain influx and consumption rates in these women than in the "typical" control patients (Kt,app = 0.45 to 1.10 mmol/L versus 0.10 mmol/L; T(max)/v(met) = 2.55 to 3.19 versus 7.8 to 14.0). Such variations seem to be major causative factors for the individual vulnerability to PKU.